Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET
- PMID: 2867601
- DOI: 10.1126/science.2867601
Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET
Abstract
D2 dopamine receptors in the putamen of living human subjects were characterized by using the selective, high-affinity D2 dopamine receptor antagonist carbon-11-labeled raclopride and positron emission tomography. Experiments in four healthy men demonstrated saturability of [11C]raclopride binding to an apparently homogeneous population of sites with Hill coefficients close to unity. In the normal putamen, maximum binding ranged from 12 to 17 picomoles per cubic centimeter and dissociation constants from 3.4 to 4.7 nanomolar. Maximum binding for human putamen at autopsy was 15 picomoles per cubic centimeter. Studies of [11C]raclopride binding indicate that clinically effective doses of chemically distinct neuroleptic drugs result in 85 to 90 percent occupancy of D2 dopamine receptors in the putamen of schizophrenic patients.
Similar articles
-
N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic.Psychiatry Res. 1998 Jun 30;82(3):147-60. doi: 10.1016/s0925-4927(98)00020-1. Psychiatry Res. 1998. PMID: 9754439 Clinical Trial.
-
D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.Arch Gen Psychiatry. 1990 Mar;47(3):213-9. doi: 10.1001/archpsyc.1990.01810150013003. Arch Gen Psychiatry. 1990. PMID: 1968328
-
Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.Arch Gen Psychiatry. 1988 Jan;45(1):71-6. doi: 10.1001/archpsyc.1988.01800250087012. Arch Gen Psychiatry. 1988. PMID: 2892477
-
The current status of PET scanning with respect to schizophrenia.Neuropsychopharmacology. 1992 Aug;7(1):41-54. Neuropsychopharmacology. 1992. PMID: 1388021 Review.
-
Raclopride, a new selective ligand for the dopamine-D2 receptors.Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):559-68. doi: 10.1016/0278-5846(88)90001-2. Prog Neuropsychopharmacol Biol Psychiatry. 1988. PMID: 2975809 Review.
Cited by
-
Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson's Disease-Potential Biomarkers and Therapeutic Targets.Int J Mol Sci. 2023 Dec 1;24(23):17037. doi: 10.3390/ijms242317037. Int J Mol Sci. 2023. PMID: 38069360 Free PMC article. Review.
-
Kinetic properties of the accumulation of 3H-raclopride in the mouse brain in vivo.Naunyn Schmiedebergs Arch Pharmacol. 1989 Jul;340(1):6-12. doi: 10.1007/BF00169199. Naunyn Schmiedebergs Arch Pharmacol. 1989. PMID: 2797215
-
Remoxipride--a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers.Psychopharmacology (Berl). 1988;95(2):157-61. doi: 10.1007/BF00174501. Psychopharmacology (Berl). 1988. PMID: 2901121
-
An integrative framework for perceptual disturbances in psychosis.Nat Rev Neurosci. 2019 Dec;20(12):763-778. doi: 10.1038/s41583-019-0234-1. Nat Rev Neurosci. 2019. PMID: 31712782 Review.
-
Biodistribution and radiation dosimetry of [11C]raclopride in healthy volunteers.Eur J Nucl Med Mol Imaging. 2005 Aug;32(8):952-8. doi: 10.1007/s00259-005-1783-2. Epub 2005 Apr 20. Eur J Nucl Med Mol Imaging. 2005. PMID: 15841376 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources